Holland Alday

Dr. Holland Alday is a researcher focused on developing new drugs for parasitic infections, particularly targeting Toxoplasma gondii, Plasmodium spp., and Babesia spp. His work includes identifying and advancing compounds from the Global Health Chemical Diversity Library and collaborating with researchers like Stone Doggett, MD and Mike Riscoe, PhD on endochin-like quinolones (ELQs).

He holds a B.S. from the Georgia Institute of Technology (2000), followed by an M.D. and Ph.D. from the University of Mississippi Medical Center (2009). He completed a residency in Internal Medicine at the University of Utah (2012) and a Fellowship in Infectious Diseases at Oregon Health & Science University (2014). He is certified by the American Board of Internal Medicine in Internal Medicine (2013) and Infectious Diseases (2014).

His research interests center on antiparasitic drug development, with a focus on understanding molecular mechanisms of action for potential therapeutic agents. He investigates compounds targeting mitochondrial electron transport pathways in parasites, such as cytochrome b inhibition, and evaluates their efficacy both in vitro and in vivo. His work bridges pharmacology, microbiology, and tropical medicine to address unmet needs in treating neglected parasitic diseases.

His publications span drug discovery methodologies and mechanistic studies, with recent work emphasizing advancements in toxoplasmosis treatment and antiparasitic compound evaluation. Earlier research involved biochemical analysis of drug interactions with tubulin and sedimentation velocity techniques.

No scientific awards are explicitly mentioned in the text. Collaboration details indicate ongoing work with Stone Doggett and Mike Riscoe on ELQ drug development, but no specific advising roles or grant information is provided.